Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, Germing U, Sperr WR, Reiter A, Wolf D, Arock M, Haferlach T, Horny HP.

Int J Mol Sci. 2019 Feb 12;20(3). pii: E789. doi: 10.3390/ijms20030789. Review.

2.

Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation Syndrome.

Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, Nedoszytko B, Siebenhaar F, Sperr WR, Oude Elberink JNG, Butterfield JH, Alvarez-Twose I, Sotlar K, Reiter A, Kluin-Nelemans HC, Hermine O, Gotlib J, Broesby-Olsen S, Orfao A, Horny HP, Triggiani M, Arock M, Schwartz LB, Metcalfe DD.

J Allergy Clin Immunol Pract. 2019 Feb 5. pii: S2213-2198(19)30056-X. doi: 10.1016/j.jaip.2019.01.006. [Epub ahead of print] Review.

3.

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, Bonifacio M, Bonadonna P, Gleixner KV, Hadzijusufovic E, Perkins C, Hartmann K, Illerhaus A, Merante S, Elena C, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, David Fuchs, Greul R, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Al-Ali HK, Morren MA, Varkonyi J, Zink A, Niedoszytko M, Niederwieser D, Malcovati L, Reiter A, Kennedy V, Gotlib J, Lortholary O, Hermine O, Arock M, Kluin-Nelemans H, Sperr WR; Study Group of the European Competence Network on Mastocytosis (ECNM).

J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87. doi: 10.1016/j.jaip.2018.09.024. Epub 2018 Nov 8. Review.

PMID:
30416055
4.

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.

Willmann M, Hadzijusufovic E, Hermine O, Dacasto M, Marconato L, Bauer K, Peter B, Gamperl S, Eisenwort G, Jensen-Jarolim E, Müller M, Arock M, Vail DM, Valent P.

Vet Comp Oncol. 2019 Mar;17(1):1-10. doi: 10.1111/vco.12440. Epub 2018 Sep 24. Review.

PMID:
30136349
5.

The underestimated role of basophils in Ph+ chronic myeloid leukaemia.

Valent P, Horny HP, Arock M.

Eur J Clin Invest. 2018 Oct;48(10):e13000. doi: 10.1111/eci.13000. Epub 2018 Aug 6. Review.

6.

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P.

Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018 Jul 17.

PMID:
30018080
7.

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.

Bibi S, Arock M.

Immunol Allergy Clin North Am. 2018 Aug;38(3):527-543. doi: 10.1016/j.iac.2018.04.007. Review.

PMID:
30007468
8.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Don Yun H, Felices M, Vallera DA, Hinderlie P, Cooley S, Arock M, Gotlib J, Ustun C, Miller JS.

Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176. No abstract available.

9.

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.

Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B, Gleixner KV, Hartmann K, Butterfield JH, Metcalfe DD, Valent P.

Haematologica. 2018 Nov;103(11):1760-1771. doi: 10.3324/haematol.2018.195867. Epub 2018 Jul 5. Review.

10.

Mast cell activation syndrome: Importance of consensus criteria and call for research.

Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Reiter A, Gotlib J, Castells M, Milner JD, Carter MC, Komarow H, Radia D, Pardanani A, Sotlar K, Triggiani M, Horny HP, Arock M, Schwartz LB, Metcalfe DD.

J Allergy Clin Immunol. 2018 Sep;142(3):1008-1010. doi: 10.1016/j.jaci.2018.06.004. Epub 2018 Jun 19. No abstract available.

PMID:
29928922
11.

Acute mast cell leukemia: A rare but highly aggressive hematopoietic neoplasm.

Costopoulos M, Uzunov M, Bories D, Charlotte F, Maloum K, Arock M.

Diagn Cytopathol. 2018 Jul;46(7):639-641. doi: 10.1002/dc.23965. Epub 2018 May 7. No abstract available.

PMID:
29736992
12.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P.

Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8.

13.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

14.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP.

EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. Review.

15.

Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, Gleixner KV, Blatt K, Sperr WR, Manley PW, Hermine O, Kluin-Nelemans HC, Arock M, Horny HP, Reiter A, Gotlib J.

Ann Oncol. 2017 Oct 1;28(10):2367-2376. doi: 10.1093/annonc/mdx290. Review.

PMID:
28945834
16.

MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.

Ducassou S, Prouzet-Mauléon V, Deau MC, Brunet de la Grange P, Cardinaud B, Soueidan H, Quelen C, Brousset P, Pasquet JM, Moreau-Gaudry F, Arock M, Mahon FX, Lippert E.

J Pathol. 2017 Jul;242(3):347-357. doi: 10.1002/path.4908. Epub 2017 May 29.

PMID:
28418072
17.

Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Schwartz LB, Broesby-Olsen S, Bindslev-Jensen C, Kovanen PT, Galli SJ, Austen KF, Arber DA, Horny HP, Arock M, Metcalfe DD.

Cancer Res. 2017 Mar 15;77(6):1261-1270. doi: 10.1158/0008-5472.CAN-16-2234. Epub 2017 Mar 2. Review.

18.

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.

Ustun C, Williams S, Skendzel S, Kodal B, Arock M, Gotlib J, Vallera DA, Cooley S, Felices M, Weisdorf D, Miller J.

Am J Hematol. 2017 May;92(5):E66-E68. doi: 10.1002/ajh.24673. Epub 2017 Feb 24. No abstract available.

19.

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M.

Leukemia. 2017 Apr;31(4):788-797. doi: 10.1038/leu.2017.15. Epub 2017 Jan 16. Review.

PMID:
28090091
20.

A new therapeutic advance for symptomatic systemic mastocytosis?

Arock M.

Lancet. 2017 Feb 11;389(10069):576-578. doi: 10.1016/S0140-6736(16)31655-5. Epub 2017 Jan 7. No abstract available.

PMID:
28069280
21.

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.

Lyberg K, Ali HA, Grootens J, Kjellander M, Tirfing M, Arock M, Hägglund H, Nilsson G, Ungerstedt J.

Oncotarget. 2017 Feb 7;8(6):9647-9659. doi: 10.18632/oncotarget.14181.

22.

A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.

Bibi S, Zhang Y, Hugonin C, Mangean MD, He L, Wedeh G, Launay JM, Van Rijn S, Würdinger T, Louache F, Arock M.

Oncotarget. 2016 Dec 13;7(50):82985-83000. doi: 10.18632/oncotarget.12824.

23.

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.

Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, Horny HP, Hartmann K, Sotlar K, Damaj G, Hermine O, Verstovsek S, Metcalfe DD, Gotlib J, Akin C, Valent P.

Haematologica. 2016 Oct;101(10):1133-1143. Review.

24.

Mast cell sarcoma: new cases and literature review.

Monnier J, Georgin-Lavialle S, Canioni D, Lhermitte L, Soussan M, Arock M, Bruneau J, Dubreuil P, Bodemer C, Chandesris MO, Lortholary O, Hermine O, Damaj G.

Oncotarget. 2016 Oct 4;7(40):66299-66309. doi: 10.18632/oncotarget.11812. Review.

25.

Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients.

Rouet A, Aouba A, Damaj G, Soucié E, Hanssens K, Chandesris MO, Livideanu CB, Dutertre M, Durieu I, Grandpeix-Guyodo C, Barète S, Bachmeyer C, Soria A, Frenzel L, Fain O, Grosbois B, de Gennes C, Hamidou M, Arlet JB, Launay D, Lavigne C, Arock M, Lortholary O, Dubreuil P, Hermine O, Georgin-Lavialle S.

Medicine (Baltimore). 2016 Jun;95(24):e3901. doi: 10.1097/MD.0000000000003901.

26.

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27. No abstract available.

27.

Mast cell differentiation: still open questions?

Arock M.

Blood. 2016 Jan 28;127(4):373-4. doi: 10.1182/blood-2015-12-686592.

28.

How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5.

Langenfeld F, Guarracino Y, Arock M, Trouvé A, Tchertanov L.

PLoS One. 2015 Dec 30;10(12):e0145142. doi: 10.1371/journal.pone.0145142. eCollection 2015.

29.

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.

Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hägglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P.

J Allergy Clin Immunol. 2016 Jan;137(1):35-45. doi: 10.1016/j.jaci.2015.08.034. Epub 2015 Oct 21. Review.

PMID:
26476479
30.

Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity.

Rabenhorst A, Leja S, Schwaab J, Gehring M, Förster A, Arock M, Reiter A, Raap U, Hartmann K.

J Allergy Clin Immunol. 2016 Jan;137(1):314-318.e5. doi: 10.1016/j.jaci.2015.07.006. Epub 2015 Aug 20. No abstract available.

PMID:
26299988
31.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9.

32.

Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.

Arock M, Akin C, Hermine O, Valent P.

Eur J Haematol. 2015 Jun;94(6):474-90. doi: 10.1111/ejh.12544. Epub 2015 Mar 26. Review.

PMID:
25753531
33.

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC, Hermine O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwaab J, Triggiani M, Horny HP, Metcalfe DD, Reiter A, Valent P.

Leukemia. 2015 Jun;29(6):1223-32. doi: 10.1038/leu.2015.24. Epub 2015 Feb 4. Review.

34.

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.

Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P.

Oncotarget. 2015 Feb 20;6(5):3071-84.

35.

Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.

Valent P, Sotlar K, Sperr WR, Reiter A, Arock M, Horny HP.

Leuk Res. 2015 Jan;39(1):1-5. doi: 10.1016/j.leukres.2014.09.010. Epub 2014 Sep 30. Review.

36.

The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment.

Basse C, Arock M.

Int J Cancer. 2015 Dec 15;137(12):2785-94. doi: 10.1002/ijc.29347. Epub 2014 Dec 1. Review.

37.

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.

Valent P, Berger J, Cerny-Reiterer S, Peter B, Eisenwort G, Hoermann G, Müllauer L, Mannhalter C, Steurer M, Bettelheim P, Horny HP, Arock M.

Ann Hematol. 2015 Feb;94(2):223-31. doi: 10.1007/s00277-014-2207-9. Epub 2014 Sep 11.

38.

The serum tryptase test: an emerging robust biomarker in clinical hematology.

Valent P, Sperr WR, Sotlar K, Reiter A, Akin C, Gotlib J, Horny HP, Arock M.

Expert Rev Hematol. 2014 Oct;7(5):683-90. doi: 10.1586/17474086.2014.955008. Epub 2014 Aug 28. Review.

39.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis.

Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M; European Competence Network on Mastocytosis.

Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436. Epub 2014 May 19.

PMID:
24836395
40.

Molecular defects in mastocytosis: KIT and beyond KIT.

Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M.

Immunol Allergy Clin North Am. 2014 May;34(2):239-62. doi: 10.1016/j.iac.2014.01.009.

PMID:
24745672
41.

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M.

Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27.

42.

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.

Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hägglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP.

Ann Oncol. 2014 Sep;25(9):1691-700. doi: 10.1093/annonc/mdu047. Epub 2014 Mar 27. Review.

43.

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.

Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M.

Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442. Review.

44.

Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis.

Kakeda M, Arock M, Schlapbach C, Yawalkar N.

J Am Acad Dermatol. 2014 Apr;70(4):683-690.e1. doi: 10.1016/j.jaad.2013.12.002. Epub 2014 Feb 9.

PMID:
24521827
45.

ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Chèze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O.

PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.

46.

Distinctive serum miRNA profile in mouse models of striated muscular pathologies.

Vignier N, Amor F, Fogel P, Duvallet A, Poupiot J, Charrier S, Arock M, Montus M, Nelson I, Richard I, Carrier L, Servais L, Voit T, Bonne G, Israeli D.

PLoS One. 2013;8(2):e55281. doi: 10.1371/journal.pone.0055281. Epub 2013 Feb 13.

47.

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P.

Blood. 2013 Mar 28;121(13):2393-401. doi: 10.1182/blood-2012-09-458521. Epub 2013 Jan 16.

48.

ICON: Eosinophil Disorders.

Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ.

World Allergy Organ J. 2012 Dec;5(12):174-81. doi: 10.1097/WOX.0b013e31827f4192. No abstract available.

49.

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, Gleixner KV, Grattan C, Hadzijusufovic E, Hägglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude-Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Várkonyi J, Yavuz S, Hartmann K.

Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20. Review.

PMID:
23179435
50.

Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.

Bougherara H, Georgin-Lavialle S, Damaj G, Launay JM, Lhermitte L, Auclair C, Arock M, Dubreuil P, Hermine O, Poul MA.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):62-9. doi: 10.1016/j.clml.2012.08.004. Epub 2012 Nov 3.

PMID:
23127495

Supplemental Content

Support Center